The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.5 - 1.5 µg/ml. Detects a band of approximately 180 kDa (predicted molecular weight: 192 kDa).
Use at an assay dependent concentration. Peptide ELISA: antibody detection limit dilution 1:8000.
Use at an assay dependent concentration.
Promotes the exchange of GDP by GTP. Activates specific Rho GTPase family members, thereby inducing various signaling mechanisms that regulate neuronal shape, growth, and plasticity, through their effects on the actin cytoskeleton. Induces lamellipodia independent of its GEF activity.
Isoform 2 is brain specific. Highly expressed in cerebral cortex, putamen, amygdala, hippocampus and caudate nucleus. Weakly expressed in brain stem and cerebellum. Isoform 4 is expressed in skeletal muscle.
Genetic variation in KALRN is associated with susceptibility to coronary heart disease type 5 (CHDS5) [MIM:608901]. CHD is the leading cause of death and disability worldwide. CHD is multifactorial disease with a strong genetic component. Classic epidemiologic studies have revealed many risk factors for CHD, including age, sex, hypertension, dyslipidemia, diabetes mellitus, smoking, and physical inactivity.
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. Contains 1 CRAL-TRIO domain. Contains 2 DH (DBL-homology) domains. Contains 1 fibronectin type-III domain. Contains 1 Ig-like C2-type (immunoglobulin-like) domain. Contains 2 PH domains. Contains 1 protein kinase domain. Contains 2 SH3 domains. Contains 5 spectrin repeats.
The two GEF domains catalyze nucleotide exchange for RAC1 and RhoA which are bound by DH1 and DH2 respectively. The two GEF domains appear to play differing roles in neuronal development and axonal outgrowth. SH3 1 binds to the first GEF domain inhibiting GEF activity only when in the presence of a PXXP peptide, suggesting that the SH3 domain/peptide interaction mediates binding to GEF1. CRK1 SH3 domain binds to and inhibits GEF1 activity.
Cytoplasm. Cytoplasm > cytoskeleton. Associated with the cytoskeleton.
Huntingtin associated protein interacting protein (duo) antibody
Huntingtin-associated protein-interacting protein antibody
Kalirin (isoform 2) antibody
Protein Duo antibody
RhoGEF kinase antibody
Serine/threonine kinase with Dbl and pleckstrin homology domains antibody
Serine/threonine-protein kinase with Dbl- and pleckstrin homology domain antibody
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - KALRN antibody (ab52012)Image kindly supplied by Dr Janine Magg through Abreview
ab52012 staining KALRN in adult brain tissue by Immunohistochemistry (paraffin embedded sections). Tissue was fixed with paraformaldehyde and a heat mediated antigen retrieval step performed using citrate buffer. Tissues were then blocked with 15% serum for 45 minutes at 20°C followed by incubation with the primary antibody, at a 1/250 dilution, for 24 hours at 4°C. A Biotin-conjugated rabbit anti-goat IgG was used as secondary antibody at a 1/250 dilution. Upper image: Un-treated. Lower image: Treated with peptide to KALRN. Counterstained with Hämalaun.
All lanes : Anti-KALRN antibody (ab52012) at 1/500 dilution
Lane 1 : Whole tissue lysate prepared from mouse brain, treated with peptide. Lane 2 : Whole cell lysate prepared from mouse brain cells over-expressing KALRN (with FLAG-tag) treated with peptide. Lane 3 : Whole cell lysate prepared from mouse brain cells over-expressing KALRN, with FLAG-tag, detected with anti-FLAG antibody. Lane 4 : Whole tissue lysate prepared from mouse brain Lane 5 : Whole cell lysate prepared from mouse brain cells over-expressing KALRN, with FLAG-tag.
Lysates/proteins at 30 µg per lane.
Secondary Donkey anti-goat IgG conjugated to HRP at 1/10000 dilution Developed using the ECL technique
Performed under non-reducing conditions.
Predicted band size : 192 kDa Observed band size : 192 kDa
Exposure time : 1 minute
Image kindly supplied by Dr Janine Magg through Abreview